Anti-PD-1 antibody

CStone Pharmaceuticals announced Wednesday that it has entered into a strategic partnership and exclusive licensing agreement with Shenyang Sunshine Pharmaceutical, a subsidiary of 3SBio Inc., for anti-PD-1 antibody Nofazinlimab in mainland China.

FAST NEWS: CStone licenses PD-1 cancer drug to 3SBio for China

The latest: CStone Pharmaceuticals (2616.HK) announced Wednesday that it has exclusively licensed Shenyang Sunshine Pharmaceutical, a subsidiary of 3SBio Inc. (1530.HK), to develop, register, manufacture and commercialize its anti-PD-1 antibody Nofazinlimab…
2616.HK

Recent Articles

RELATED ARTICLES

  1. Genfleet bio
    Cancer drug maker Genfleet joins Hong Kong IPO influx
  2. A blockbuster cancer drug? TYK’s claims go under the microscope
    2410.HK
  3. Cancer drug maker Biostar shines on Hong Kong market debut
    2563.HK
  4. Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
  5. Earnings blow for CSPC Pharma as the state drives a hard bargain
    1093.HK
  6. Everest Medicines drives growth with AI-powered mRNA pipeline
    1952.HK
  7. No respite for RemeGen as problems and losses pile up
    9995.HK 688331.SHG
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva